Patents by Inventor Alex Stenzler

Alex Stenzler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7520866
    Abstract: Topical exposure of nitric oxide gas to wounds such as chronic non-healing wounds may be beneficial in promoting healing of the wound and in preparing the wound bed for further treatment and recovery. Nitric oxide gas may be used, for example, to reduce the microbial infection and burden on these wounds, manage exudate secretion by reducing inflammation, upregulate expression of endogenous collagenase to locally debride the wound, and regulate the formation of collagen. High concentration of nitric oxide ranging from about 160 to 400 ppm may be used without inducing toxicity in the healthy cells around a wound site. Additionally, exposure to the high concentration for a first treatment period reduces the microbial burden and inflammation at the wound site and increase collagenase expression to debride necrotic tissue at the wound site.
    Type: Grant
    Filed: July 13, 2006
    Date of Patent: April 21, 2009
    Assignees: Sensormedics Corporation, Pulmonox Technologies Corporation
    Inventors: Alex Stenzler, Chris C Miller
  • Patent number: 7516742
    Abstract: A device and method is disclosed for delivering NO to a patient. The device utilizes a single controller that controls two separate flow controllers to deliver an oxygen-containing gas and a NO-containing gas to the patient to provide NO-containing gas at a flow profile that is proportional or quasi-proportional to a flow profile of the oxygen-containing gas throughout patient inspiration. The controller further comprises logic for setting a nitric oxide delivery profile comprising at least two different concentrations of nitric oxide containing gas and for automatically switching between the at least two different concentrations of nitric oxide containing gas on a timed basis.
    Type: Grant
    Filed: September 23, 2005
    Date of Patent: April 14, 2009
    Assignees: Cardinal Health 207, Inc., Pulmonox Technologies Corporation
    Inventors: Alex Stenzler, Christopher C. Miller, Bevin McMullin
  • Publication number: 20090056708
    Abstract: The present invention is directed to the administration of aerosolized particles to specific area of the lungs, and in particular to the targeted delivery of aerosolized pharmaceutical formulations to a specific area of the lungs. More specifically, the present invention relates to devices and methods for depositing aerosolized particles to a specific area of the lungs by regulating aerosolizing parameters of the device. The present invention also relates to devices, systems and methods for disease management, where the aerosolizing parameters are adjusted based on monitoring at least one health parameter.
    Type: Application
    Filed: July 31, 2008
    Publication date: March 5, 2009
    Applicants: ACTIVAERO GMBH, CARDINAL HEALTH 207, INC.
    Inventors: Alex Stenzler, William C. Zimlich, Gerhard Scheuch, Bernhard Mullinger, Tobias Kolb, Tobias Hoffmann, Andreas Wenker, Axel Fischer, Sascha Roeder
  • Publication number: 20080287861
    Abstract: Topical exposure of nitric oxide gas to wounds such as chronic non-healing wounds may be beneficial in promoting healing of the wound and in preparing the wound bed for further treatment and recovery. Nitric oxide gas may be used, for example, to reduce the microbial infection and burden on these wounds, manage exudate secretion by reducing inflammation, upregulate expression of endogenous collagenase to locally debride the wound, and regulate the formation of collagen. High concentration of nitric oxide ranging from about 160 to 400 ppm may be used without inducing toxicity in the healthy cells around a wound site. Additionally, exposure to the high concentration for a first treatment period reduces the microbial burden and inflammation at the wound site and increase collagenase expression to debride necrotic tissue at the wound site.
    Type: Application
    Filed: October 31, 2007
    Publication date: November 20, 2008
    Inventors: Alex Stenzler, Christopher C. Miller
  • Publication number: 20080206364
    Abstract: The present invention relates to compositions and methods for treatment of a patient affected with an autoimmune disorder, and in an embodiment, a skin-related autoimmune disorder. The treatment involves the application of gaseous nitric oxide to an affected patient, and in an embodiment, to the skin of an affected patient.
    Type: Application
    Filed: October 12, 2007
    Publication date: August 28, 2008
    Applicant: Nitric Biotherapeutics, Inc.
    Inventors: Frank J. McCaney, Alex Stenzler, Chris Miller
  • Publication number: 20080173311
    Abstract: A method of topically treating the respiratory tract of a mammal with nitric oxide exposure includes the steps of providing a source of nitric oxide containing gas and delivering the nitric oxide containing gas nasally to the upper respiratory tract of the mammal. Also provided are several designs for a nasal delivery device for the controlled nasal deliver the nitric oxide containing gas.
    Type: Application
    Filed: December 20, 2007
    Publication date: July 24, 2008
    Applicants: PULMONOX TECHNOLOGIES CORPORATION, SENSORMEDICS CORPORATION
    Inventors: Christopher Miller, Alex Stenzler
  • Publication number: 20080167603
    Abstract: A respiratory assist device and method for the prevention of ventilator acquired pneumonia in a patient is described. The respiratory assist device administers nitric oxide to the oropharyngeal area in order to decontaminate or prevent the contamination of secretions that collect in the oropharyngeal area during intubation of the patient. The respiratory assist device and method may be adapted for use, for example, as an endotracheal tube or as a tracheotomy tube.
    Type: Application
    Filed: October 30, 2007
    Publication date: July 10, 2008
    Inventors: Alex Stenzler, Arthur Samuel Slutsky
  • Publication number: 20080160107
    Abstract: The present invention relates to compositions and methods for treatment of blood and blood products using gaseous nitric oxide. The treatment involves the contacting blood or a blood product with gaseous nitric oxide.
    Type: Application
    Filed: October 31, 2007
    Publication date: July 3, 2008
    Applicants: Nitric Biotherapeutics, Inc., Cardinal Health 207, Inc.
    Inventors: Frank J. McCaney, Alex Stenzler, Chris Miller
  • Patent number: 7335181
    Abstract: A method of topically treating the respiratory tract of a mammal with nitric oxide exposure includes the steps of providing a source of nitric oxide containing gas and delivering the nitric oxide containing gas nasally to the upper respiratory tract of the mammal. Also provided are several designs for a nasal delivery device for the controlled nasal deliver the nitric oxide containing gas.
    Type: Grant
    Filed: April 14, 2005
    Date of Patent: February 26, 2008
    Assignees: Pulmonox Technologies Corporation, Sensormedics Corporation
    Inventors: Christopher Miller, Alex Stenzler
  • Publication number: 20080029093
    Abstract: A method and corresponding device are described for combating microbes and infections by delivering intermittent high doses of nitric oxide to a mammal for a period of time and which cycles between high and low concentration of nitric oxide gas. The high concentration of nitric oxide is preferably delivered intermittently for brief periods of time that are interspersed with periods of time with either no nitric oxide delivery or lower concentrations of nitric oxide. The method is advantageous because at higher concentration, nitric oxide gas overwhelms the defense mechanism of pathogens that use the mammalian body to replenish their thiol defense system. A lower dose or concentration of nitric oxide gas delivered in between the bursts of high concentration nitric oxide maintains nitrosative stress pressure on the pathogens and also reduces the risk of toxicity of nitric oxide gas.
    Type: Application
    Filed: May 11, 2005
    Publication date: February 7, 2008
    Inventors: Alex Stenzler, Chris Miller, Bevin McMullin
  • Publication number: 20070144515
    Abstract: A method and corresponding device are described for combating microbes and infections by delivering intermittent high doses of nitric oxide to a mammal for a period of time and which cycles between high and low concentration of nitric oxide gas. The high concentration of nitric oxide is preferably delivered intermittently for brief periods of time that are interspersed with periods of time with either no nitric oxide delivery or lower concentrations of nitric oxide. The method is advantageous because at higher concentration, nitric oxide gas overwhelms the defense mechanism of pathogens that use the mammalian body to replenish their thiol defense system. A lower dose or concentration of nitric oxide gas delivered in between the bursts of high concentration nitric oxide maintains nitrosative stress pressure on the pathogens and also reduces the risk of toxicity of nitric oxide gas.
    Type: Application
    Filed: November 10, 2006
    Publication date: June 28, 2007
    Inventors: Alex Stenzler, Chris Miller, Bevin McMullin
  • Publication number: 20070088316
    Abstract: Topical exposure of nitric oxide gas to wounds such as chronic non-healing wounds may be beneficial in promoting healing of the wound and in preparing the wound bed for further treatment and recovery. Nitric oxide gas may be used, for example, to reduce the microbial infection and burden on these wounds, manage exudate secretion by reducing inflammation, upregulate expression of endogenous collagenase to locally debride the wound, and regulate the formation of collagen. High concentration of nitric oxide ranging from about 160 to 400 ppm may be used without inducing toxicity in the healthy cells around a wound site. Additionally, exposure to the high concentration for a first treatment period reduces the microbial burden and inflammation at the wound site and increase collagenase expression to debride necrotic tissue at the wound site.
    Type: Application
    Filed: July 13, 2006
    Publication date: April 19, 2007
    Inventors: Alex Stenzler, Chris Miller
  • Publication number: 20070074724
    Abstract: Provided is a universal interface adapted for providing continuous positive airway pressure to a patient when the interface is used with a standard ventilator. The interface is configured to operate at a supply pressure no greater than about 120 centimeters of H2O in order to deliver pressure to the patient of up to about 15 cm of H2O at a flow rate of up to about 12 liters/minute. The universal interface may comprise an interface body having a space pair of breathing passageways intersecting a corresponding of supply passageways. Each one of the breathing passageways is comprised of a patient passageway and an exhalation passageway. Each one of the supply passageways includes a jet venturi having a taper portion. Each one of the exhalation passageways includes a taper portion which tapers outwardly along a direction from the patient passageway toward the exhalation passageway.
    Type: Application
    Filed: September 30, 2005
    Publication date: April 5, 2007
    Inventors: Steven Duquette, Alex Stenzler, Steve Han
  • Patent number: 7122018
    Abstract: Topical exposure of nitric oxide gas to wounds such as chronic non-healing wounds may be beneficial in promoting healing and preparing the wound bed for further treatment and recovery. Nitric oxide gas may be used to reduce the microbial infection, manage exudates secretion by reducing inflammation, upregulate expression of endogenous collagenase to locally debride the wound, and regulate the formation of collagen. High concentration of nitric oxide ranging from 160–400 ppm may be used without inducing toxicity in the healthy cells around a wound site. Exposure to the high concentration for a first treatment period reduces the microbial burden and inflammation, and increases collagenase expression to debride necrotic tissue at the wound site. After a first treatment period, a second treatment period at a lower concentration of nitric oxide, preferably ranging from 5–20 ppm may be used to restore the balance of nitric oxide and induce collagen expression aiding in the wound closure.
    Type: Grant
    Filed: December 23, 2004
    Date of Patent: October 17, 2006
    Assignees: Sensormedics Corporation, Pulmonox Technologies Corporation
    Inventors: Alex Stenzler, Chris C Miller
  • Publication number: 20060207594
    Abstract: A device and method is disclosed for delivering NO to a patient. The device utilizes a single controller that controls two separate flow controllers to deliver an oxygen-containing gas and a NO-containing gas to the patient to provide NO-containing gas at a flow profile that is proportional or quasi-proportional to a flow profile of the oxygen-containing gas throughout patient inspiration. The controller further comprises logic for setting a nitric oxide delivery profile comprising at least two different concentrations of nitric oxide containing gas and for automatically switching between the at least two different concentrations of nitric oxide containing gas on a timed basis.
    Type: Application
    Filed: September 23, 2005
    Publication date: September 21, 2006
    Inventors: Alex Stenzler, Christopher Miller, Bevin McMullin
  • Patent number: 7108666
    Abstract: Disclosed is a method and device for performing forced expiratory maneuver in an infant to assess the infant's pulmonary function. Under this method, the infant's lungs are synchronously inflated to super-atmospheric levels synchronous with the infant's natural tidal inspiration for a plurality of consecutive respiratory cycles. The end-expiratory CO2 levels in the infant's respiration are measured during the test. When the end-expiratory CO2 concentration decreases from the baseline by a pre-defined amount, the infant lungs are rapidly inflated to substantially total lung volume and rapidly deflated to produce a maximum forced expiration. The pre-defined amount of change in CO2 concentration is usually determined by the testing clinician. Typical concentration drop in CO2 levels, for example, ranges between 4 and 8 mmHg. But the decrease may also be as little as 2 mmHg or as much as 15 mmHg, depending on the testing clinician.
    Type: Grant
    Filed: January 7, 2003
    Date of Patent: September 19, 2006
    Assignee: Sensormedics Corporation
    Inventor: Alex Stenzler
  • Publication number: 20050217679
    Abstract: A method of topically treating the respiratory tract of a mammal with nitric oxide exposure includes the steps of providing a source of nitric oxide containing gas and delivering the nitric oxide containing gas nasally to the upper respiratory tract of the mammal. Also provided are several designs for a nasal delivery device for the controlled nasal deliver the nitric oxide containing gas.
    Type: Application
    Filed: April 14, 2005
    Publication date: October 6, 2005
    Inventors: Christopher Miller, Alex Stenzler
  • Publication number: 20050191372
    Abstract: Topical exposure of nitric oxide gas to wounds such as chronic non-healing wounds may be beneficial in promoting healing of the wound and in preparing the wound bed for further treatment and recovery. Nitric oxide gas may be used, for example, to reduce the microbial infection and burden on these wounds, manage exudate secretion by reducing inflammation, upregulate expression of endogenous collagenase to locally debride the wound, and regulate the formation of collagen. High concentration of nitric oxide ranging from about 160 to 400 ppm may be used without inducing toxicity in the healthy cells around a wound site. Additionally, exposure to the high concentration for a first treatment period reduces the microbial burden and inflammation at the wound site and increase collagenase expression to debride necrotic tissue at the wound site.
    Type: Application
    Filed: December 23, 2004
    Publication date: September 1, 2005
    Inventors: Alex Stenzler, Chris Miller
  • Publication number: 20050137521
    Abstract: A device for the topical delivery of nitric oxide gas to an infected area of skin includes a source of nitric oxide gas, a bathing unit, a flow control valve, and a vacuum unit. The bathing unit is adapted to surround the area of the infected skin and form a substantially air-tight seal with the skin surface. The bathing unit is also in fluidic communication with the source of nitric oxide. The flow control valve is position downstream of the source of nitric oxide and upstream of the bathing unit. The flow control valve controls the amount of nitric oxide gas that is delivered to the bathing unit. The vacuum unit is positioned downstream of the bathing unit and is used to withdraw gas from the bathing unit. Application of nitric oxide gas to the infected area of skin reduces levels of bacteria in the infected area and promotes the healing process.
    Type: Application
    Filed: September 17, 2004
    Publication date: June 23, 2005
    Inventor: Alex Stenzler
  • Publication number: 20050076907
    Abstract: A device and method is disclosed for delivering NO to a patient. The device utilizes a single controller that controls two separate flow controllers to deliver an oxygen-containing gas and a NO-containing gas to the patient. The flow profiles of the oxygen-containing gas and the NO-containing gas are controlled by the controller. In one aspect of the invention, the flow profile of the NO-containing gas is proportional to the flow profile of the oxygen-containing gas throughout patient inspiration. In this regard, the patient receives a steady concentration of NO. In another aspect of the invention, the flow profile of the NO-containing gas is quasi-proportional to the flow profile of the oxygen-containing gas. In this regard, the NO-containing gas flow profile is altered to provide an increased concentration of NO either at the beginning or end of inspiration. In one aspect, the delivery device is used with mechanically-ventilated patients.
    Type: Application
    Filed: July 21, 2004
    Publication date: April 14, 2005
    Inventor: Alex Stenzler